SCHEMBL76084

SCHEMBL76084

C#CCOC(OCC#C)c1ccc(Cl)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
IDO1 P14902 3/20 0.36
TDO2 P48775 3/20 0.36
TSHR P16473 4/20 0.35
HIF1A Q16665 3/20 0.35
MAPK1 P28482 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
HPGD P15428 2/20 0.34
TP53 P04637 1/20 0.34
ADRB2 P07550 1/20 0.34
PYCR1 P32322 1/20 0.34
POLB P06746 1/20 0.34
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
SLC6A2 P23975 1/20 0.33
CYP19A1 P11511 2/20 0.33
AOC3 Q16853 1/20 0.33
CYP2A6 P11509 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77607 0.82 TSHR (0.39) LMNASMN1; SMN2IDO1TDO2TSHR
SCHEMBL14558224 0.81 ADRB2 (0.41) LMNASMN1; SMN2IDO1TDO2TSHR
SCHEMBL14609441 0.81 ADRB2 (0.41) LMNASMN1; SMN2IDO1TDO2TSHR
SCHEMBL11314272 0.80 PYCR1 (0.35) LMNASMN1; SMN2TDP1PYCR1SLC6A3
SCHEMBL6455092 0.79 NPC1 (0.38) LMNASMN1; SMN2TSHRSLC6A4SLC6A3
SCHEMBL5917965 0.78 IDO1 (0.32) LMNASMN1; SMN2IDO1TDO2TSHR
SCHEMBL12281775 0.77 PYCR1 (0.41) TSHRMAPK1TDP1PYCR1POLB
SCHEMBL75610 0.75 PPARG (0.46) LMNATSHRPOLBMEN1KMT2A
SCHEMBL5917972 0.75 PPARG (0.36) LMNATSHRMEN1KMT2AGPX4
Hydrochloric Acid SCHEMBL5918049 0.74 PPARG (0.44) LMNATSHRPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
EP-1919857-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF Syngeta Participations AG (CH) 2008-05-14 EP disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof OPRM1, OPRD1, ADRA1D LMNA 1215/4885SMN1; SMN2 666/4885IDO1 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.